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The synthesis of the endo five-membered cycloortho-palladated benzophenone imines 37 
[Pd{C6H4(Ph)C=NR}]2(μ-X)2 [1 (X = OAc), 2 (X = Cl), a (R = phenyl), b (R = 1-naphthyl), c (R = 38 
benzyl), d (R = α-methylbenzyl)], and trans-N,P-[Pd{C6H4(Ph)C=NR}X(PPh3)] [3 (X = OAc), 4 (X = 39 
Cl), a (R = phenyl), b (R = 1-naphthyl), c (R = benzyl), d (R = α-methylbenzyl)] and the X-ray molecular 40 
structure of 1a, 1c, 1d, 4a, 4b, and 4c are reported. The antitumor activity, DNA interaction, and 41 
cathepsin B inhibition of palladium compounds a−d were studied and compared with those previously 42 
reported for palladium compounds e with R = H and compound 4f analogous to 4e but with a 43 
platinum(II) center. The IC50 values against a panel of human cancer cell lines allowed the 44 
establishment of a qualitative relationship between their structure and antitumor activity. Compounds 45 
3e, 4e, and 4f were the most active ones in relation to their in vitro anticancer activity. Compounds 3e 46 
and 4e were about 4 times more active than cisplatin against the MDA-MB-231 and MCF-7 breast 47 
human cancer lines, and compound 4f was about 4 times more active than cisplatin against the cisplatin-48 
resistant HCT-116 colon human cancer cell line. In addition, compound 3e was 3 times less cytotoxic 49 
than cisplatin toward the quiescent HUVEC cells. Accumulation of palladium compounds e and b in the 50 
MDA-MB-231 cell line was considerably greater than that of cisplatin in the same cell line, but 51 
palladium compounds b were noncytotoxic. Some of these complexes altered the DNA tertiary structure 52 
in a similar way to cisplatin but at higher concentration, and most cytotoxic ones did not present a high 53 









In recent years, coordination and organometallic palladium(II) compounds have been explored as an 61 
alternative to platinum-(II) compounds as anticancer drugs, in part due to the similarity of their 62 
substitution reactions.1,2 A significant difference between the two metal centers is the higher kinetic 63 
lability of palladium(II) compared to that of platinum(II). This renders palladium(II) less attractive for 64 
anticancer studies since hydrolysis of Pd−Cl bonds is quite fast and gives way to very reactive species 65 
that are unable to reach the target biomolecules into the cancer cells.3 In spite of this, the use of bulky 66 
monodentate ligands or chelate bidentate or terdentate ligands has provided palladium(II) compounds 67 
that are less reactive and with promising cytotoxicity against different cancer cell lines.2 68 
The cytotoxicity of a significant number of cyclopalladated compounds has been explored against a 69 
variety of cancer cell lines with interesting outcomes and with some chances of progressing for 70 
evaluation as drug candidates.4−20 For instance, compounds A and B in Figure 1 presented IC50 values 71 
against the B16-next2 murine melanoma cell line less than 1.25 μM. Compound B was the most potent 72 
in vivo, delaying tumor growth and prolonging animal survival in mice subcutaneously inoculated with 73 
the B16F10-Nex2 melanoma cell line. On the other hand, cyclopalladated compound C with a bridging 74 
1,1′-bis(diphenylphosphane)ferrocene showed a notable cathepsin B inhibitory activity, with the 75 
potential to treat metastatic cancers.10−18 It should be noted that cyclopalladated compounds A−C 76 
shown in Figure 1 were patented as antitumor drugs.18 77 
Recently, we have reported the synthesis of the cyclopalladated benzophenone imines 1e−4e and the 78 
cycloplatinated benzophenone imine 4f (see Scheme 1 for their structural formula), and we have studied 79 
their (i) antitumor activity toward MDA-MB-231 and MCF-7 breast and cisplatinresistant HCT-116 80 
colon human cancer cell lines, (ii) interaction with pBluescript SK + plasmid DNA, (iii) cathepsin B 81 
inhibition test, and (iv) antibacterial and antioxidant activity.19,20 Noteworthy, compounds 3e and 4e 82 
were about 4 times more active than cisplatin against the MDA-MB-231 and MCF-7 human breast 83 
cancer lines, and compound 4f was also about 4 times more active than cisplatin against the 84 
cisplatinresistant HCT-116 human colon cancer cell line. In addition, compounds 1e−4e and 4f 85 
presented a moderate antibacterial and antioxidant activity.20 86 
Following these studies, we report herein the preparation of cyclopalladated benzophenone imines a−d 87 
(Scheme 1) and the study of (i) the antitumor activity against MDA-MB-231 and MCF-7 human breast 88 
and cisplatin-resistant HCT-116 human colon cancer cell lines for compounds a−d, (ii) the cellular 89 
accumulation of the palladium compounds b and e, (iii) the interaction of compounds a−d with the 90 
pBluescript SK + plasmid DNA, (iv) the interaction of compounds 2b and 2d with the pBluescript SK 91 
+ plasmid DNA in the presence of topoisomerase I, and (v) the cathepsin B inhibition test for the most 92 
cytotoxic palladium compounds a−d. The cytotoxicity of compound 3e, one of the most antiproliferative 93 
complexes, was also studied toward the human umbilical vein endothelial cells (HUVEC) in quiescent 94 
and normal culture conditions. It should be noted that these cells in quiescent conditions are used as a 95 
model for nonproliferative normal cells. These analyses are compared with those previously reported by 96 
our group for palladium compounds e and for the platinum compound 4f.19,20 97 
The aim of these studies is to establish structure−activity relationships upon the structure of the proposed 98 





RESULTS AND DISCUSSION 102 
 103 
Synthesis and Characterization of the Compounds.  104 
The structural formula and the numbering of the compounds under study are given in Scheme 1. 105 
Benzophenone imines a−d were prepared by a condensation reaction between benzophenone and the 106 
corresponding amine using TiCl4 as Lewis acid promoter and drying agent in a molar ratio of 1:1:5 107 
TiCl4/benzophenone/amine by an adaptation of a previously reported method.21 Imines a−d were 108 
obtained in moderate to high yield and were characterized by EM, IR, and 1H and 13C{1H} NMR. 109 
Imine e (Ph2C=NH) was available commercially and was used as received. Compounds 1e−4e and 4f 110 
were prepared according to the procedures previously described in our research group.19,20 Thus, 111 
treatment of imine e (Ph2C=NH) with Pd(OAc)2 in a 1:1 molar ratio in acetic acid at 60 °C for 24 h 112 
generated the dinuclear cyclopalladated compound 1e with acetato bridging ligands in high yield. A 113 
subsequent metathesis reaction of compound 1e with LiCl in acetone at room temperature produced the 114 
dinuclear cyclopalladated compound 2e with chlorido bridging ligands. The mononuclear compounds 115 
3e and 4e were obtained by bridge-splitting reactions of the dinuclear compounds 1e and 2e with PPh3 116 
in acetone at room temperature. Mixture A, the precursor of compound 4f, was prepared by reaction of 117 
cis-[PtCl2(DMSO)2] and NaOAc in a 1:1 molar ratio with an excess of benzophenone imine in dry 118 
methanol under nitrogen and at reflux for 24 h. A subsequent reaction of mixture A with PPh3 yielded 119 
compound 4f. The purity of compounds 1e−4e and 4f was checked by IR and 1H NMR, and purity of 120 
compounds 3e, 4e, and 4f was checked in addition by 31P{1H} NMR. 121 
Compounds 1−4 from series a−d were obtained by an adaptation of the procedures given above for 122 
compounds 1e−4e. It should be noted that the synthesis of compounds 2a, 2c, and 4c was previously 123 
claimed,22,23 but their detailed preparative method and their characterization data were not reported, 124 
except for the C, H, and N elemental analyses of 2a.23 According to the literature,24 we propose an 125 
endo fivemembered ortho-cyclopalladated structure for the palladium compounds a−d. The endo 126 
descriptor denotes that the C=N bond is included in the metalacycle.25 This assumption was established 127 
unambiguously by the XRD molecular crystal structure determination of 1aꞏ2MeOH, 1c, 1d, 4a, 128 
4bꞏMeOH, and 4cꞏMeOH (see below). Compounds 1−4 from series a−d afforded satisfactory EM, IR, 129 
and 1H NMR. In addition, the 31P{1H} NMR spectra of compounds 3 and 4 from series a−d were also 130 
consistent with their proposed structure.26 131 
Details of the preparative method and isolation in pure form of the benzophenone imines a−d and their 132 
cyclopalladated derivatives 1−4 and selected characterization data for these compounds are given in the 133 
Supporting Information. 134 
XRD Molecular Structures of 1a, 1c, 1d, 4a, 4b, and 4c. 135 
Figures 2−7 show ball-and-stick models of the molecular structure of 1a, 1c, 1d, 4a, 4b, and 4c 136 
determined by singlecrystal X-ray diffraction analysis. Single crystals of 1aꞏ2MeOH, 1c, 1d, 4a, 137 
4bꞏMeOH, and 4cꞏMeOH were grown by slow evaporation of the solvents of a solution of the 138 
corresponding compound 1 in CH2Cl2, MeOH, and acetone in 1:1:1 volume ratio or by the slow 139 
evaporation of the solvents of a solution of the corresponding compound 4 in CH2Cl2 and MeOH in a 140 
volume ratio of 1:1. The crystal structure reports and CIF files for these X-ray molecular crystal structure 141 
determinations are given in the Supporting Information. These structures have been also deposited in 142 
the Cambridge Crystallographic Data Centre with the following deposition numbers: 1025622 (4bꞏ 143 
MeOH), 1025623 (1c), 1025624 (1d), 1025625 (1aꞏ2MeOH), 1025626 (4a), and 1025627 (4cꞏMeOH). 144 
These molecular structures confirm the proposed structural formula for the compounds under study. 145 
Thus, all these molecules can be classified as endo five-membered orthocyclopalladated benzophenone 146 
imines. In addition, molecules 1a, 1c, and 1d are dinuclear with the acetato ligands bridging two 147 
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cyclopalladated units and present a trans-folded structure, and molecules 4a, 4b, and 4c are mononuclear 148 
and present a trans-N,P configuration. 149 
In the crystal of compound 1d, both halves of the molecules were equivalent because these molecules 150 
were situated over crystallographic binary proper rotation axes, but in the crystals of 1aꞏ2MeOH and 1c, 151 
the molecules of compounds 1a and 1c presented two nonequivalent halves, which differed between 152 
them in small differences in distances, angles, and torsion angles. 153 
Distances and angles around of the palladium(II) centers for all these molecules were between the 154 
normal intervals.26−29 The chelate bite angles were those from the coordination sphere of the 155 
palladium(II) centers with the largest deviations from the ideal angles of 90 and 180° and were 80.77(9) 156 
and 81.27(9)° for 1a, 81.66(14) and 81.26(13)° for 1c, 81.19(14)° for 1d, 80.70(8) Å for 4a, 81.11(7)° 157 
for 4b, and 80.69(7) Å for 4c. The five-membered metalacycles in all these molecules were planar, and 158 
maximum deviated atoms from the five-membered planar metalacycles were C1 0.064 Å and C21 −0.78 159 
Å for 1a, C39 −0.011(3) Å and N1 0.068(3) for 1c, C6 0.008(4) Å and C1 −0.008(4) for 1d, N1 −0.038(2) 160 
for 4a, N1 0.021(2) for 4b, and N1 0.049 Å for 4c.  161 
In compounds 1, Pd−O bonds trans to the metalated carbon atoms were longer than Pd−O bonds trans 162 
to the iminic nitrogen atom [Pd1−O1 2.1247(16) Å and Pd2−O3 2.1573(16) Å but Pd1−O4 2.0576(17) 163 
Å and Pd2−O2 2.0374(16) Å for 1a, Pd1−O2 2.155(2) Å and Pd2−O3 2.147(3) Å but Pd1−O4 2.055(2) 164 
and Pd2−O1 2.042(2) Å for 1c, and Pd1−O1 2.141(3) but Pd1−O2 2.050(3) Å for 1d]. These results 165 
were in agreement with the greater trans influence of the palladated carbon atom in relation to the iminic 166 
nitrogen atom.30 Also, the greater trans influence of the phosphorus atom of PPh3 in relation to the 167 
oxygen atom of the acetate ligand explained the longer Pd−N bonds in compounds 4 in relation to 168 
compounds 1 [Pd1−N1 2.1028(19) Å for 4a, Pd1−N1 2.1162(17) Å for 4b, Pd1−N1 2.0964(14) Å for 169 
4c but Pd1−N1 2.0191(19) Å and Pd2−N2 2.0177(19) Å for 1a, Pd1−N2 2.010(3) Å and Pd2−N1 170 
2.022(3) Å for 1c, and Pd1−N1 2.038(3) Å for 1d].30 171 
The angle between the palladacycles in compounds 1a, 1c, and 1d were 25.11, 27.66(14), and 54.16°, 172 
respectively, and the distances between palladium atoms were 2.90693(3), 2.8698(4), and 3.204 Å, 173 
respectively. These distances were too long to be considered a palladium−palladium single bond.31 174 
The angles between the palladacycles and the phenyls bonded to the methinic carbon atoms in these 175 
molecules were 59.38 and 58.78° for 1a, 78.4(2) and 62.42(18)° for 1c, 86.1(2)° for 1d, 85.11(11)° for 176 
4a, 66.69(12)° for 4b, and 76.75° for 4c. In compounds 1a and 4a, the angles between the phenyls bonded 177 
to the iminic nitrogen atoms and the palladacycles were 61.57 and 61.24° for 1a and 79.75(11)° for 4a, 178 
and the angle between the 1-naphthyl group bonded to the iminic nitrogen atom and the palladacycle 179 
was 75.23(10)° in compound 4b. 180 
Finally, in all these molecules, the metalated phenyl and the metalacycle were almost coplanar, with the 181 
angles between them being 7.05 and 5.82° for 1a, 1.73(16) and 7.23(15)° for 1c, 4.15(18)° for 1d, 182 
5.50(11)° for 4a, 1.00(10)° for 4b, and 4.52° for 4c. 183 
Biological Studies. Antiproliferative Activity. The cytotoxicity of palladium compounds a−d against 184 
MDA-MB-231 and MCF-7 breast and cisplatin-resistant HCT-116 colon adenocarcinoma human cell 185 
lines was studied, and their IC50 values against the precedent cell lines are collected in Table 1. For 186 
comparison, the IC50 values against the above cited cell lines for cisplatin, free imines, palladium 187 
compounds e, and platinum compound 4f are also included in Table 1. It should be noted that the IC50 188 
values for palladium compounds e and compound 4f against the cancer cell lines cited above have been 189 
previously reported by our research group.19,20 Table 1 gives also the clog P for the compounds under 190 
study. This is the calculated logarithmic value of the n-octanol/water partition coefficient of the 191 
compound under consideration and can be related to its lipophilicity.32 192 
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For a better understanding of Table 1, we have included a color code for the cells. Thus, green ones 193 
mean that the compounds under consideration are more cytotoxic than cisplatin against the specified 194 
tumor cell lines; yellow ones are compounds that are cytotoxic but less cytotoxic than cisplatin; red ones 195 
are compounds that are not cytotoxic with IC50 values greater than 100 μM, and cells not filled with 196 
color indicate compounds that are poorly cytotoxic (IC50 > 50 μM) or noncytotoxic. Cells 197 
corresponding to cisplatin are filled with blue color. 198 
From data given in Table 1, the following trend for the in vitro antitumor activity of compounds 1−4 199 
from series a−e and compound 4f can be derived: 3e ≈ 4e (more cytotoxic than cisplatin) > 4f (more 200 
cytotoxic than cisplatin) > 2e ≈ 1e (less cytotoxic than cisplatin) > 2d ≈ 2c ≈ 2a (less cytotoxic than 201 
cisplatin) > 3a (less cytotoxic than cisplatin) > the other compounds (inactive or poorly active). 202 
This trend seems to indicate that an accurate balance between hydrophilicity and lipophilicity could be 203 
regulating the in vitro antitumor activity of these cyclometalated benzophenone imines. For instance, 204 
for palladium compounds e, which should be the most hydrophilic ones due to the presence of the N−H 205 
function in their structural formula, when passing from 3e and 4e to 1e and 2e, a substantial drop in 206 
activity is observed. This should be ascribed to the decrease in lipophilicity on going from 3e and 4e to 207 
1e and 2e (see clog P values in Table 1). On the other hand, for palladium compounds a, c, and d, which 208 
are more lipophilic than palladium compounds e, since in this series the group bonded to the iminic 209 
nitrogen is phenyl, benzyl, or α-methylbenzyl, respectively, the maximum activity corresponds to 210 
compounds 2a, 2c, and 2d, which are the ones with the lowest lipophilicity of these series (see clog P 211 
values in Table 1). Finally, compound 2b is not active at all since this compound is more lipophilic (R 212 
= 1-naphthyl) than compounds 2a (R = phenyl), 2c (R = benzyl), and 2d (R = α-methylbenzyl). At 213 
present, we cannot find a reliable explanation for the IC50 value of compound 3a (12 μM) toward the 214 
MDA-MB-231 cell line. In addition, the great cytotoxicity observed for palladium compounds e could 215 
also be related to their better solubility and/or to the ability of their NH moiety to establish hydrogen 216 
bonds with a target biomolecule.33 217 
It should be noted that water solubility for the organometallic compounds under study is in fact very 218 
low, but we expect that, once in solution in the biological media, palladium compounds a−d should be 219 
converted into the ionic aqua complexes [Pd(C,N)(H2O)2]X (X = OAc or Cl) (compounds I) and trans-220 
N,P-[Pd(C,N)(PPh3)(H2O)]X (X = OAc or Cl) (compounds II) by substitution of their chlorido ligands 221 
by water molecules. Therefore, we propose that the responsible species for the biological activities 222 
studied here are the ionic aqua complexes I and II commented above. Similar aqua complexes were 223 
proposed to be the responsible species for the biological activities observed for palladium compound e 224 
and compound 4f.19,20 225 
The cytotoxicity of compound 3e, one of the most potent complexes in the cancer cell lines evaluated, 226 
and cisplatin was also tested against HUVEC cells in starving culture conditions, in which cells are 227 
almost quiescent or in low proliferative conditions, and in normal cell culture conditions, in which cells 228 
are in highly proliferative conditions (see Experimental Section for the details). Table 2 gives the IC50 229 
values for these studies. Interestingly, compound 3e was 2 times and 1.5 times less cytotoxic than 230 
cisplatin toward the HUVEC cells in starving and in normal cell culture conditions, respectively. 231 
Cell Accumulation. The cellular accumulation of platinum drugs in vivo is well-documented, and it is 232 
believed to be dependent on both passive diffusion and active transport. Active transport can involve 233 
the entry into the cell with the help of copper transporters and organic cation transporters, as well as 234 
active efflux of the drug by copper efflux transporters.34 The relationship between lipophilicity, cellular 235 
accumulation, and cytotoxicity of oxaliplatin derivatives with different substituents at the 4 position of 236 
the cyclohexane ring has been investigated. In this study, the more lipophilic compounds revealed a 237 
lower cytotoxicity, although the early influx rate (passive diffusion) was increased in the case of more 238 
lipophilic platinum complexes. Alterations in the reactivity in the intracellular environment of the 239 
platinum compounds with bulky substituents or increased sequestration of the most lipophilic platinum 240 
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complexes in cellular organelles such as lysosomes could be responsible for their reduced cytotoxicity 241 
in the investigated cell lines.35 This explanation could account for the lower cytotoxicity observed for 242 
palladium compounds a−d with regard to that of palladium compounds e and the absence of 243 
antiproliferative activity of palladium compounds b, which present the bulkier and more lipophilic 244 
substituent in series a−d. 245 
To get more insight on the antitumor activity of the benzophenone cyclopalladated imines, the cellular 246 
accumulation of palladium compounds b and e was studied and compared with that of cisplatin. In these 247 
studies, palladium was used as a measure of the cellular accumulation of the palladium compounds, and 248 
platinum was used as a measure of the cellular accumulation of cisplatin. Mole of palladium or platinum 249 
per cell was determined by ICP-MS. Table 3 gives the cellular accumulation for the tested compounds 250 
and for cisplatin after 4 h of incubation on the breast cancer cell line MDA-MB-231. 251 
The accumulation of the tested compounds in the cell line studied was considerably greater than that of 252 
cisplatin, and compounds 3e and 4e, which are the compounds with the highest antitumor activity against 253 
the MDA-MB-231 cell line, were those with the highest amounts of palladium accumulated per cell. 254 
The accumulation of these latter compounds was about 50 and 100 times higher than that of cisplatin. 255 
Interestingly, the noncytotoxic compounds 1b−4b were accumulated on the MDA-MB-231 cell line in 256 
quite high amounts. This result suggests that these compounds could be noncytotoxic because of their 257 
bulky 1-naphthyl group, which should render their palladium(II) centers less reactive, or because of their 258 
accumulation in cellular organelles such as lysosomes due to their elevated lipophilicity.35 259 
DNA Interaction. The binding of palladium compounds a−d to DNA was studied by their ability to 260 
modify the electrophoretic mobility of the supercoiled closed circular (ccc) and the open circular (oc) 261 
forms of pBluescript SK + plasmid DNA. 262 
Figure 8 shows the electrophoretic mobility of pBluescript SK + plasmid DNA incubated with the free 263 
ligands a−d and palladium compounds a−d at increasing concentrations. To provide a basis for 264 
comparison, incubation of DNA with cisplatin and ethidium bromide (EB) was also performed using 265 
the same concentrations and conditions. The electrophoretic mobility of pBluescript SK + plasmid DNA 266 
incubated with palladium compounds e and compound 4f was previously reported by our research group 267 
and has also been included in Figure 8 for a comparative purpose.19,20  268 
As expected, cisplatin greatly altered the electrophoretic mobility of pBluescript SK + plasmid DNA at 269 
2.5 μM, but for EB, only a very slight decrease in the electrophoretic mobility of DNA was detected 270 
between 25 and 100 μM.19 For the free ligands a−d, no shift in the rate of migration of the supercoiled 271 
band was observed. 272 
Palladium compounds a−e were less efficient than cisplatin in removing the supercoils from DNA, in 273 
spite of the fact that some were more cytotoxic than cisplatin. Only compound 3b produced at 10 μM 274 
concentration (lane 4), a significant effect on the mobility of pBluescript DNA. At 25 μM concentration 275 
(lane 5), complexes 1a−1c induced significant changes in plasmid DNA mobility. Complexes 1a−1e, 276 
2e, and 3a−3d showed the same effect of coalescence and positive supercoiling observed for cisplatin 277 
but at a higher concentration. Compound 4f was also less efficient than cisplatin for removing the 278 
supercoils from pBluescript SK + plasmid DNA, suggesting that the unwinding of the DNA is not the 279 
key factor responsible for its cytotoxicity.20 280 
Compounds with the greatest effect on DNA mobility did not necessarily correlate to those with the 281 
lowest IC50 values. For instance, modifications induced on DNA mobility for 1a were greater than those 282 
produced for 2a, but 2a was more potent than 1a in the three cancer cell lines assayed. On the other hand, 283 
noncytotoxic cyclopalladated compounds (i.e., 1b and 3b, IC50 values >100 μM) induced significant 284 
changes on DNA mobility. It is hypothesized that, in the conditions of the gel mobility assay, compounds 285 




To evaluate the ability of the investigated complexes to intercalate into DNA, a topoisomerase-based 288 
gel assay was performed on 2b and 2d. Supercoiled pBluescript plasmid DNA was incubated in the 289 
presence of topoisomerase I at increasing concentrations of compounds 2a and 2b. The results are given 290 
in Figure 9, and they show that 2b and 2d do not prevent unwinding of DNA by the action of 291 
topoisomerase I, indicating that these compounds are neither intercalators nor inhibitors of 292 
topoisomerase I.8 293 
The precedent results suggest that DNA is not a primary target biomolecule for the cyclopalladated and 294 
cycloplatinated benzophenone imines under study. 295 
Cathepsin B Inhibition. Cathepsin B is a cysteine metalloprotease highly upregulated in a wide variety 296 
of cancers by mechanisms ranging from gene amplification to post-transcriptional modification. The 297 
exact role of cathepsin B in solid tumors has yet to be defined, but it has been proposed to participate in 298 
metastasis, angiogenesis, and tumor progression. Recently, compounds based on palladium, platinum, 299 
ruthenium, rhenium, gold, and tellurium were shown to be effective inhibitors of cathepsin B.36 In 300 
addition, an excellent correlation between cathepsin B inhibition and cytotoxicity for some dinuclear 301 
biphosphane palladacycles37 and mononuclear platinacycles containing a fluorinated phosphane38 has 302 
been reported. In spite of these results, we have recently reported20 that compounds 1e−4e and 4f are 303 
not efficient inhibitors of cathepsin B although they are quite cytotoxic in vitro. 304 
Following these studies, we have determined the cathepsin B inhibition activity for compounds 2a, 2c, 305 
2d, and 3a, which are the more active ones from series a−d in relation to their in vitro antitumor activity. 306 
The results are given in Table 4. This table also includes our previously reported results for the cathepsin 307 
B inhibition test for palladium compounds e and compound 4f for a comparative purpose.20 308 
Compounds 2a, 2c, 2d, and 3a inhibited cathepsin B in a dose-dependent manner, but they were not 309 
efficient as cathepsin B inhibitors since 50% of residual activity of the enzyme is not observed until 310 
quite high concentrations, greater than 50 or 100 μM depending on the compound. These results confirm 311 
that cathepsin B is not a primary target biomolecule for the cyclopalladated and cycloplatinated 312 






The present study and previous ones19,20 confirm that compounds 3e, 4e, and 4f are the most active in 317 
vitro antitumor agents against the evaluated cell lines between a quite large number of cyclometalated 318 
benzophenone imines studied. Compounds 3e and 4e were about 4 times more active than cisplatin 319 
against the MDA-MB-231 and MCF-7 breast human cancer lines, and compound 4f is about 4 times 320 
more active than cisplatin against the cisplatin-resistant HCT-116 colon human cancer cell line. The in 321 
vitro cytotoxicity of the cyclopalladated benzophenone imines a−e against the studied cancer cell lines 322 
seems to be regulated by an adequate balance between their hydrophilicity and lipophilicity. In addition, 323 
accumulation of palladium compounds e and b in the MDAMB-231 cell line was considerably greater 324 
than that of cisplatin, but palladium compounds b were noncytotoxic. Furthermore, compound 3e, one 325 
of the most potent complexes in the cell lines evaluated, was 3 times and 1.5 times less cytotoxic than 326 
cisplatin toward HUVEC cells in starving (quiescent) and normal cell culture conditions, respectively. 327 
Concerning the determination of plausible primary target biomolecules for these cyclopalladated and 328 
cycloplatinated benzophenone imines, DNA migration studies and cathepsin B inhibition tests suggest 329 






Cell Culture. Colon HCT-116 and breast cancer MCF-7 and MBA-MD-231 cells were grown as a 334 
monolayer culture in minimum essential medium (DMEM with L-glutamine, without glucose and 335 
without sodium pyruvate) in the presence of 10% heat-inactivated fetal calf serum (FCS), 10 mM D-336 
glucose, and 0.1% streptomycin/penicillin, in standard culture conditions (humidified air with 5% CO2 337 
at 37 °C). 338 
Cell Viability Assay for HC-T116, MDA-MB-231, and MCF-7Cell Lines. A stock solution (50 mM) 339 
of each compound was prepared in high-purity DMSO. Then, serial dilutions were made with 340 
DMSO/DMEM (1:1), and finally a 1:500 dilution on culture medium was prepared. Final assay 341 
concentration of DMSO was the same in all experiments and was 0.2%. The assay was performed as 342 
described.39 HCT-116, MDA-MB-231, and MCF-7 cells were plated at 5000 cells/well in 100 μL of 343 
media in tissue culture 96-well plates. After 24 h, medium was replaced by 100 μL/well of drug serial 344 
dilutions. Control wells did not contain the compounds under study. Each point concentration was run 345 
in triplicate. Reagent blanks, containing media and colorimetric reagent without cells, were run on each 346 
plate. Blank values were subtracted from test values and were routinely 5−10% of the control values. 347 
Plates were incubated 72 h. Hexosaminidase activity was measured according to the following protocol. 348 
The medium was removed, and cells were washed once with PBS. Sixty microliters of substrate solution 349 
of 7.5 mM p-nitrophenol-N-acetyl-β-D-glucosamide, 0.1 M sodium citrate at pH 5.0, and 0.25% Triton 350 
X-100 was added to each well and incubated at 37 °C for 1−2 h. After this incubation time, a bright 351 
yellow color appeared. Then, the plates were developed by adding 90 μL of developer solution (50 mM 352 
glycine, pH 10.4; 5 Mm EDTA), and the absorbance was recorded at 410nm. 353 
Cell Viability Assay for the HUVEC Cells. Cytotoxicity in normal cells was assayed using primary 354 
human umbilical vein endothelial cells, at passage 6−8. Viability was assayed in two culture conditions: 355 
highly proliferative, where 10% of FCS, supplements, and growth factors were included in culture 356 
media; low proliferative, where cells were almost quiescent, by restraining FCS at 2% with no 357 
supplements or growth factors. Assays were done as described for tumor cell lines, plating 5000 cell/well 358 
for each growing condition. 359 
Cell Accumulation. Cell accumulation of compounds was measured in the MDA-MB-231 cell line. A 360 
total of 1 × 106 cells was seeded in 6 mm tissue culture dishes for 16 h in DMEM/high glucose plus 361 
10% FCS. Then, compounds were added at 50 μM for 4 h at 37 °C, 5% CO2. Cisplatin was used as a 362 
positive control at the same concentration and DMSO as a vehicle control. After treatment, cells were 363 
washed twice with PBS, tripsinized, and harvested in PBS. Cell suspension was centrifuged, and pellets 364 
were digested with 12 M HCl and diluted to 1.2 M HCl. Each treatment was done in duplicate. The 365 
samples were analyzed by ICP-MS. 366 
DNA Migration Studies. A stock solution (10 mM) of each compound was prepared in high-purity 367 
DMSO. Then, serial dilutions were made in Milli-Q water (1:1). Plasmid pBluescript SK+ was obtained 368 
using a kit as described by the manufacturer. Interaction of drugs with pBluescript SK+ plasmid DNA 369 
was analyzed by agarose gel electrophoresis following a modification of the method previously 370 
described.40 Plasmid DNA aliquots (40 μg mL−1) were incubated in TE buffer (10 mM Tris-HCl, 1 371 
mM EDTA, pH 7.5) with different concentrations of test compounds ranging from 0 to 200 μM at 37°C 372 
for 24 h. Final DMSO concentration in the reactions was always lower than 1%. For comparison, 373 
cisplatin and ethidium bromide were used as reference controls. Aliquots of 20 μL of the incubated 374 
solutions of compounds containing 0.8 μg of DNA were subjected to 1% agarose gel electrophoresis in 375 
TAE buffer (40 mM Tris-acetate, 2 mM EDTA, pH 8.0). The gel was stained in TAE buffer containing 376 
EB (0.5 mg mL−1) and visualized and photographed under UV light.  377 
11 
 
Topoisomerase I-based experiments were performed as described previously.41 Supercoiled 378 
pBluescript DNA, obtained as described above, was treated with topoisomerase I in the absence or 379 
presence of increasing concentrations of compounds 2b and 2d. Assay mixtures contained supercoiled 380 
pBluescript DNA (0.8 μg), calf thymus topoisomerase I (3 units), and complexes 2b and 2d (0−100 μM) 381 
in 20 μL of Tris-HCl buffer (pH 7.5) containing 175 mM KCl, 5 mM MgCl2, and 0.1 mM EDTA. 382 
Ethidium bromide (10 μM) was used as a control of intercalating agents and etoposide (100 μM) as a 383 
control of the nonintercalating agent. Reactions were incubated for 30 min at 37°C and stopped by the 384 
addition of 2 μL of agarose gel loading buffer. Samples were then subjected to electrophoresis, and 385 
DNA bands were stained with ethidium bromide as described above. 386 
Cathepsin B Inhibition Assay. The colorimetric cathepsin B assay was performed as described by 387 
Casini et al.42 with few modifications. Briefly, the reaction mixture contained 100 mM sodium 388 
phosphate (pH 6.0), 1 mM EDTA, and 200 μM sodium Ncarbobenzoxy-L-lysine p-nitrophenyl ester as 389 
substrate. To have the enzyme catalytically active before each experiment, the active site of the cysteine 390 
was reduced by treatment with dithiothreitol (DTT). For this purpose, 5 mM DTT was added to the 391 
cathepsin B sample, before dilution, and incubated 1 h at 30 °C. To test the inhibitory effect of the 392 
palladium compounds on cathepsin B, activity measurements were performed in triplicate using fixed 393 
concentrations of enzyme (500 nM) and substrate (200 μM). The palladium compounds were used at 394 
concentrations ranging from 50 to 100 μM. Previous to the addition of substrate, cathepsin B was 395 
incubated with the different compounds at 25 °C for 2 h. The cysteine proteinase inhibitor E-64 was 396 
used as a positive control of cathepsin B inhibition. Complete inhibition was achieved at 10 μM 397 
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Legends to figures  491 
 492 
Figure 1. Structural formula of cyclopalladated compounds with chances of progressing for evaluation 493 
as drug candidates. 494 
 495 
Figure 2. XRD molecular structure of compound 1a. Selected bond distances (Å) and angles (deg): 496 
Pd1−C9 1.950(2), Pd1−N1 2.0191(19), Pd1−O4 2.0576(17), Pd1−O1 2.1247(16), Pd1−Pd2 2.9069(3), 497 
Pd2−C21 1.943(2), Pd2−N2 2.0177(19), Pd2−O2 2.0374(16), Pd2−O3 2.1573(16), C9−Pd1−N1 498 
80.77(9), C9−Pd1−O4 93.80(8), N1−Pd1−O4 173.36(7), C9−Pd1−O1 176.17(8), N1−Pd1−O1 95.47(7), 499 
O4−Pd1−O1 89.89(7), C21−Pd2−N2 81.27(9), C21−Pd2−O2 92.79(8), N2−Pd2−O2 173.53(7), 500 
C21−Pd2−O3 176.31(8), N2−Pd2−O3 95.15(7), O2−Pd2−O3 90.83(7). 501 
 502 
Figure 3. XRD molecular structure of compound 1c. Selected bond distances (Å) and angles (deg): 503 
Pd1−C44 1.968(3), Pd2−C3 1.947(3), Pd1−O2 2.155(2), Pd2−O3 2.147(3), Pd1−N2 2.010(3), Pd2−N1 504 
2.022(3), Pd1−O4 2.055(2), Pd2−O1 2.042(2), Pd1−Pd2 2.8698(4), O2−Pd1−C44 176.26(12), 505 
O3−Pd2−C3 176.91(12), O4−Pd1−N2 173.65(11), O1−Pd2−N1 174.78(11), C44−Pd1−N2 81.66(14), 506 
C3−Pd2−N1 81.26(13), C44−Pd1−O4 93.70(12), C3−Pd2−O1 93.56(12), O4−Pd1−O2 89.13(10), 507 
O1−Pd2−O3 89.42(10), N2−Pd1−O2 95.33(12), N1−Pd2−O3 95.78(10). 508 
 509 
Figure 4. XRD molecular structure of compound 1d. Selected bond distances (Å) and angles (deg): 510 
Pd1−C1 1.957(4), Pd1−N1 2.038(3), Pd1−O1 2.141(3), Pd1−O2 2.050(3), Pd(1)−Pd(1) 3.2037(6), 511 
O1−Pd1−C1 171.07(13), N1−Pd1−O2 172.97(12), C1−Pd1−N1 81.19(14), C1−Pd1−O2 92.50(15), 512 
O2−Pd1−O1 87.34(11), N1−Pd1−O1 98.40(12). 513 
 514 
Figure 5. XRD molecular structure of compound 4a. Selected bond distances (Å) and angles (deg): 515 
Pd1−C31 2.015(2), Pd1−Cl1 2.3508(6), Pd1−N1 2.1028(19), Pd1−P1 2.2695(6), N1−Pd1−P1 516 
176.59(5), C(31)−Pd(1)−Cl(1) 170.94(7), C31−Pd1−N1 80.70(8), N1−Pd1−Cl1 90.86(6), P1−Pd1−Cl1 517 
92.42(2), C31−Pd1−P1 96.09(7). 518 
 519 
Figure 6. XRD molecular structure of compound 4b. Selected bond distances (Å) and angles (deg): 520 
Pd1−C23 2.0226(19), Pd1−Cl1 2.3647(10), Pd1−N1 2.1162(17), Pd1−P1 2.2651(9), Cl1−Pd1−C23 521 
172.91(6), P1−Pd1−N1 175.62(5), N1−Pd1−C23 81.11(7), Cl1−Pd1−N1 91.83(5), Cl1−Pd1−P1 522 
92.54(3), P1−Pd1−C23 94.52(6). 523 
 524 
Figure 7. XRD molecular structure of compound 4c. Selected bond distances (Å) and angles (deg): 525 
Pd(1)−C(1) 2.0135(19), Pd(1)−N(1) 2.0964(16), Pd(1)−P(1) 2.2639(6), Pd(1)−Cl(1) 2.3837(5), 526 
C(1)−Pd(1)−N(1) 80.69(7), C(1)−Pd(1)−P(1) 93.70(6), N(1)−Pd(1)−P(1) 174.15(5), C(1)−Pd(1)−Cl(1) 527 
173.10(6), N(1)−Pd(1)−Cl(1) 92.62(5), P(1)−Pd(1)−Cl(1) 92.942(19). 528 
 529 
Figure 8. Interaction of pBluescript SK + plasmid DNA (0.8 μg) with increasing concentrations of 530 
compounds under study, cisplatin and ethidium bromide. Lane 1: DNA only. Lane 2: 2.5 μM. Lane 3: 5 531 
18 
 
μM. Lane 4: 10 μM. Lane 5: 25 μM. Lane 6: 50 μM. Lane 7: 100 μM. Lane 8: 150 μM. Lane 9: 200 532 
μM; ccc = supercoiled closed circular DNA; oc = open circular DNA. 533 
 534 
Figure 9. Analysis of 2b and 2d as putative DNA intercalators or topoisomerase I inhibitors. Conversion 535 
of supercoiled pBluescript plasmid DNA (0.8 μg) to relaxed DNA by the action of topoisomerase I (3 536 
units) in the absence or in the presence of increasing amounts of compounds 2b and 2d was analyzed by 537 
agarose gel stained with ethidium bromide. EB was used as a control of intercalating agent and etoposide 538 
(E) as a control of nonintercalating agent. Lane 1: DNA only. Lane 2: 0 μM drug. Lane 3: 10 μM drug. 539 
Lane 4: 25 μM drug. Lane 5: 50 μM drug. Lane 6: 100 μM drug. Except for lane 1, all lanes included 540 
































Table 4. IC50 (μM) Values and Percent of Residual Activity of Cathepsin B at 100 μM for 565 






















aReactions and conditions: (i) TiCl4 (Lewis acid promoter and drying agent) + benzophenone + amine, 584 
toluene, 24 h, reflux, molar ratio TiCl4/benzophenone/amine = 1:1:5; (ii) benzophenone imine + 585 
Pd(OAc)2, HOAc, 60 °C, 24 h, molar ratio Pd(OAc)2/benzophenone imine = 1:1; (iii) compound 1 + 586 
LiCl excess, acetone, room temperature, 2 h; (iv) compounds 1 or 2 + PPh3, acetone, room temperature, 587 
2 h, molar ratio 1 or 2/PPh3 = 1:2; (v) cis-[PtCl2(DMSO)2], NaOAc (stoichiometric), benzophenone 588 
imine (excess), methanol, reflux, 24 h, under N2; (vi) mixture A + PPh3, acetone, room temperature, 2 589 
h, molar ratio mixture A/PPh3 = 1:1. 590 
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